An 11-year retrospective review of venlafaxine ingestion in children from the California Poison Control System

S. Doroudgar, P. J. Perry, G. D. Lackey, N. G. Veselova, H. M. Chuang, Timothy E Albertson

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Venlafaxine is commonly used in the United States for approved and non-Food and Drug Administration-approved indications in adults. It is used off-label to treat children for psychiatric diagnoses. The aim of the study was to describe venlafaxine toxicities in children and to identify the venlafaxine dose per weight that correlates with toxicities. An 11-year retrospective study of venlafaxine ingestion in children was performed using the California Poison Control System (CPCS) database. Data was extracted from phone calls received by CPCS clinicians and follow-up phone calls made to assess the patient's progress in a health-care setting. Inclusion criteria were venlafaxine ingestion cases reported to CPCS between January 2001 and December 2011, children aged 20 years and under, venlafaxine as the only ingested substance, managed in a health-care facility, and followed to a known outcome. Two hundred sixty-two cases met the study criteria. Common presentations included gastrointestinal (14.9%), altered mental status (13.7%), and tachycardia (13.4%). The majority of the cases resulted in no effect (51.5%) or minor effect (19.9%). The average estimated dose per weight was 18.3 mg/kg in all patients and 64.5 mg/kg in those experiencing moderate-to-severe adverse effects. Seizures occurred in only 4 of the 262 cases at doses ranging from 1500 to 7500 mg. Although the estimated dose per weight exceeded 10 mg/kg for the majority of the cases, only 12 cases resulted in moderate or severe outcomes. The majority of venlafaxine ingestion cases in children resulted in either no clinical effects or minor clinical effects.

Original languageEnglish (US)
Pages (from-to)767-774
Number of pages8
JournalHuman and Experimental Toxicology
Volume35
Issue number7
DOIs
StatePublished - Jul 1 2016

Fingerprint

Poisons
Eating
Control systems
Health care
Weights and Measures
Toxicity
Delivery of Health Care
Child Psychiatry
Health Facilities
Venlafaxine Hydrochloride
Mental Disorders
Tachycardia
Labels
Seizures
Retrospective Studies
Databases
Pharmaceutical Preparations

Keywords

  • children
  • human
  • poisoning
  • toxicology
  • Venlafaxine

ASJC Scopus subject areas

  • Toxicology
  • Health, Toxicology and Mutagenesis

Cite this

An 11-year retrospective review of venlafaxine ingestion in children from the California Poison Control System. / Doroudgar, S.; Perry, P. J.; Lackey, G. D.; Veselova, N. G.; Chuang, H. M.; Albertson, Timothy E.

In: Human and Experimental Toxicology, Vol. 35, No. 7, 01.07.2016, p. 767-774.

Research output: Contribution to journalArticle

Doroudgar, S. ; Perry, P. J. ; Lackey, G. D. ; Veselova, N. G. ; Chuang, H. M. ; Albertson, Timothy E. / An 11-year retrospective review of venlafaxine ingestion in children from the California Poison Control System. In: Human and Experimental Toxicology. 2016 ; Vol. 35, No. 7. pp. 767-774.
@article{f7b53a4bd1f54b25b6479c19c4688fe0,
title = "An 11-year retrospective review of venlafaxine ingestion in children from the California Poison Control System",
abstract = "Venlafaxine is commonly used in the United States for approved and non-Food and Drug Administration-approved indications in adults. It is used off-label to treat children for psychiatric diagnoses. The aim of the study was to describe venlafaxine toxicities in children and to identify the venlafaxine dose per weight that correlates with toxicities. An 11-year retrospective study of venlafaxine ingestion in children was performed using the California Poison Control System (CPCS) database. Data was extracted from phone calls received by CPCS clinicians and follow-up phone calls made to assess the patient's progress in a health-care setting. Inclusion criteria were venlafaxine ingestion cases reported to CPCS between January 2001 and December 2011, children aged 20 years and under, venlafaxine as the only ingested substance, managed in a health-care facility, and followed to a known outcome. Two hundred sixty-two cases met the study criteria. Common presentations included gastrointestinal (14.9{\%}), altered mental status (13.7{\%}), and tachycardia (13.4{\%}). The majority of the cases resulted in no effect (51.5{\%}) or minor effect (19.9{\%}). The average estimated dose per weight was 18.3 mg/kg in all patients and 64.5 mg/kg in those experiencing moderate-to-severe adverse effects. Seizures occurred in only 4 of the 262 cases at doses ranging from 1500 to 7500 mg. Although the estimated dose per weight exceeded 10 mg/kg for the majority of the cases, only 12 cases resulted in moderate or severe outcomes. The majority of venlafaxine ingestion cases in children resulted in either no clinical effects or minor clinical effects.",
keywords = "children, human, poisoning, toxicology, Venlafaxine",
author = "S. Doroudgar and Perry, {P. J.} and Lackey, {G. D.} and Veselova, {N. G.} and Chuang, {H. M.} and Albertson, {Timothy E}",
year = "2016",
month = "7",
day = "1",
doi = "10.1177/0960327115604202",
language = "English (US)",
volume = "35",
pages = "767--774",
journal = "Human and Experimental Toxicology",
issn = "0960-3271",
publisher = "SAGE Publications Inc.",
number = "7",

}

TY - JOUR

T1 - An 11-year retrospective review of venlafaxine ingestion in children from the California Poison Control System

AU - Doroudgar, S.

AU - Perry, P. J.

AU - Lackey, G. D.

AU - Veselova, N. G.

AU - Chuang, H. M.

AU - Albertson, Timothy E

PY - 2016/7/1

Y1 - 2016/7/1

N2 - Venlafaxine is commonly used in the United States for approved and non-Food and Drug Administration-approved indications in adults. It is used off-label to treat children for psychiatric diagnoses. The aim of the study was to describe venlafaxine toxicities in children and to identify the venlafaxine dose per weight that correlates with toxicities. An 11-year retrospective study of venlafaxine ingestion in children was performed using the California Poison Control System (CPCS) database. Data was extracted from phone calls received by CPCS clinicians and follow-up phone calls made to assess the patient's progress in a health-care setting. Inclusion criteria were venlafaxine ingestion cases reported to CPCS between January 2001 and December 2011, children aged 20 years and under, venlafaxine as the only ingested substance, managed in a health-care facility, and followed to a known outcome. Two hundred sixty-two cases met the study criteria. Common presentations included gastrointestinal (14.9%), altered mental status (13.7%), and tachycardia (13.4%). The majority of the cases resulted in no effect (51.5%) or minor effect (19.9%). The average estimated dose per weight was 18.3 mg/kg in all patients and 64.5 mg/kg in those experiencing moderate-to-severe adverse effects. Seizures occurred in only 4 of the 262 cases at doses ranging from 1500 to 7500 mg. Although the estimated dose per weight exceeded 10 mg/kg for the majority of the cases, only 12 cases resulted in moderate or severe outcomes. The majority of venlafaxine ingestion cases in children resulted in either no clinical effects or minor clinical effects.

AB - Venlafaxine is commonly used in the United States for approved and non-Food and Drug Administration-approved indications in adults. It is used off-label to treat children for psychiatric diagnoses. The aim of the study was to describe venlafaxine toxicities in children and to identify the venlafaxine dose per weight that correlates with toxicities. An 11-year retrospective study of venlafaxine ingestion in children was performed using the California Poison Control System (CPCS) database. Data was extracted from phone calls received by CPCS clinicians and follow-up phone calls made to assess the patient's progress in a health-care setting. Inclusion criteria were venlafaxine ingestion cases reported to CPCS between January 2001 and December 2011, children aged 20 years and under, venlafaxine as the only ingested substance, managed in a health-care facility, and followed to a known outcome. Two hundred sixty-two cases met the study criteria. Common presentations included gastrointestinal (14.9%), altered mental status (13.7%), and tachycardia (13.4%). The majority of the cases resulted in no effect (51.5%) or minor effect (19.9%). The average estimated dose per weight was 18.3 mg/kg in all patients and 64.5 mg/kg in those experiencing moderate-to-severe adverse effects. Seizures occurred in only 4 of the 262 cases at doses ranging from 1500 to 7500 mg. Although the estimated dose per weight exceeded 10 mg/kg for the majority of the cases, only 12 cases resulted in moderate or severe outcomes. The majority of venlafaxine ingestion cases in children resulted in either no clinical effects or minor clinical effects.

KW - children

KW - human

KW - poisoning

KW - toxicology

KW - Venlafaxine

UR - http://www.scopus.com/inward/record.url?scp=84973469394&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84973469394&partnerID=8YFLogxK

U2 - 10.1177/0960327115604202

DO - 10.1177/0960327115604202

M3 - Article

C2 - 26351291

AN - SCOPUS:84973469394

VL - 35

SP - 767

EP - 774

JO - Human and Experimental Toxicology

JF - Human and Experimental Toxicology

SN - 0960-3271

IS - 7

ER -